Debiopharm Group to Support Ascepion in the Development of Debio 1144
News Apr 18, 2013
Suzhou Ascepion Pharmaceuticals, Inc. (Ascepion) and Debiopharm Group™ (Debiopharm) have announced that Debiopharm will support further development in China of Debio 1144, a small molecule in preclinical development for the treatment of a large spectrum of solid tumors.
Debiopharm and Ascepion had previously signed a license agreement for the development and commercialization of Debio 1144, an orally available multikinase inhibitor.
After having generated positive preclinical results with the product, Debiopharm has decided to support Ascepion for further development of Debio 1144 in China as it is well designed for the treatment of certain types of cancers that are highly represented in China.
“This is an opportunity for Ascepion to develop an anti-cancer agent tailored to the Chinese market,” said Rolland-Yves Mauvernay, President and founder of Debiopharm Group™.
Mauvernay continued, “At Debiopharm we value sharing our competences with a Chinese company in view of developing a product with a potential to treat various cancers highly prevalent in emerging markets.”
“The disease spectrum of the Chinese population suggests the product will be well suited for its market. Thus it holds a great promise for certain cancer types in Chinese patients,” commented Dr. Shan Jiang, President and CEO of Ascepion Pharmaceuticals.
Global Experts Meeting on Frontiers in Biosimilars and Biologics Congress
Oct 24 - Oct 26, 2019